Key clinical point: Forgoing androgen deprivation
therapy cuts rather than raises overall and cardiac mortality in certain patients with prostate cancer, according to their comorbidities.
Researchers ultimately determined that intermittent androgen deprivation
does not achieve comparable survival rates compared to complete androgen deprivation
therapy, though it does provide small improvements in quality of life (i.
The team's hypothesis is that metastatic prostate cancer patients with the weakest response to androgen-deprivation therapy could be given GCP concurrently with androgen deprivation
therapy to retain Filamin A in the nucleus, thereby allowing cancer cells to die off.
The Impact of Exercise on Patients Undergoing Androgen Deprivation
Therapy for Prostate Cancer
bone loss in patients with prostate cancer.
28,29) Androgen deprivation
can be achieved surgically or by medical castration, which can be performed by the administration of estrogens and gonadotropin-releasing agonists and antagonists, and has been shown to be effective in treating advanced and metastatic disease in several large clinical trials.
9] If AR were upregulated after a prolonged period of androgen deprivation
thus making cancer cells more sensitive to anti-androgens, then we might have expected a longer period of PSA response.
NASDAQ: GTXI) today announced that the results of the Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of androgen deprivation
therapy (ADT) for advanced prostate cancer will be presented during a late breaking oral presentation at the 2008 Annual Meeting of the American Association for Cancer Research being held in San Diego April 12 - 16.
7] Medical ADT is often favoured over orchiectomy because of the potential for intermittent androgen deprivation
, lack of procedural complications and possible psychological benefits.
Although androgen deprivation
therapy is currently a treatment option for these men, the associated sequelae, including loss of libido, fatigue, anemia, cognitive impairment and osteoporosis, make this therapy unattractive to many patients.
NASDAQ: GTXI) today announced that toremifene citrate 80 mg reduced hot flashes in men with prostate cancer on androgen deprivation
therapy (ADT), a key secondary endpoint of the Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of ADT for advanced prostate cancer.
In the landmark EORTC (European Organisation for Research and Treatment of Cancer) 22863 trial, overall survival (OS) and local control were considerably improved with the use of 3 years of adjuvant androgen deprivation
therapy (ADT) when given with external beam radiotherapy (EBRT) in patients with high-risk locally advanced disease (90% had cT3/T4).